Late-stage epilepsy Xenon's lead asset azetukalner is in Phase 3 for epilepsy and is advancing in mood disorders, indicating strong cardiometabolic safety and a broad CNS focus that can be leveraged for partnerships or co-development discussions with neurology and psychiatry stakeholders.

Expanded funding A substantial public financing event raised approximately $747.5 million in gross proceeds, signaling strong investor confidence and liquidity that can support expansion opportunities, strategic partnerships, and accelerated clinical programs.

Neurology leadership Active participation and data dissemination at major neurology conferences (AAN, AES) position Xenon as a thought leader, enabling collaboration with academic centers, contract research organizations, and potential licensing partners seeking access to Kv7 and Nav1.7 programs.

Strategic CFO leadership New CFO appointment enhances financial oversight and capital deployment, making the company a more attractive partner for co-development financing, milestone-based deals, and structured collaborations with pharma and biotech developers.

Global footprint With offices in Vancouver and Boston and a scalable tech stack (AWS, Azure, analytics, and Kubernetes), Xenon presents opportunities for regional partnerships, clinical trial site expansion, and data-centric collaborations to support multicenter trials and real-world evidence generation.